全文获取类型
收费全文 | 2433篇 |
免费 | 108篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 26篇 |
妇产科学 | 81篇 |
基础医学 | 220篇 |
口腔科学 | 34篇 |
临床医学 | 262篇 |
内科学 | 739篇 |
皮肤病学 | 38篇 |
神经病学 | 104篇 |
特种医学 | 56篇 |
外科学 | 512篇 |
综合类 | 9篇 |
预防医学 | 91篇 |
眼科学 | 75篇 |
药学 | 121篇 |
肿瘤学 | 206篇 |
出版年
2024年 | 2篇 |
2023年 | 15篇 |
2022年 | 37篇 |
2021年 | 67篇 |
2020年 | 39篇 |
2019年 | 53篇 |
2018年 | 84篇 |
2017年 | 56篇 |
2016年 | 47篇 |
2015年 | 73篇 |
2014年 | 104篇 |
2013年 | 139篇 |
2012年 | 195篇 |
2011年 | 238篇 |
2010年 | 111篇 |
2009年 | 138篇 |
2008年 | 206篇 |
2007年 | 207篇 |
2006年 | 201篇 |
2005年 | 136篇 |
2004年 | 120篇 |
2003年 | 85篇 |
2002年 | 113篇 |
2001年 | 6篇 |
2000年 | 5篇 |
1999年 | 16篇 |
1998年 | 11篇 |
1997年 | 13篇 |
1996年 | 6篇 |
1995年 | 5篇 |
1994年 | 6篇 |
1993年 | 5篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1990年 | 4篇 |
1989年 | 8篇 |
1988年 | 2篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1980年 | 3篇 |
1977年 | 2篇 |
1976年 | 1篇 |
1971年 | 1篇 |
1969年 | 1篇 |
1965年 | 1篇 |
1964年 | 1篇 |
1962年 | 1篇 |
1960年 | 1篇 |
1939年 | 3篇 |
1938年 | 2篇 |
排序方式: 共有2582条查询结果,搜索用时 31 毫秒
51.
Antonios Athanasiou Adamantios Michalinos Andreas Alexandrou Sotirios Georgopoulos Evangelos Felekouras 《World journal of gastroenterology : WJG》2014,20(25):8298-8303
Arteriovenous fistulas between the inferior mesenteric artery and vein are rare, with only 26 primary and secondary cases described in the literature. Secondary fistulas occur following operations of the left hemicolon and manifest as abdominal pain, abdominal mass, gastrointestinal bleeding, colonic ischemia and portal hypertension. Symptom intensities are flow-dependent, and can range from minimal symptoms to severe heart failure due to left to right shunt. Diagnosis is usually established by radiological or intraoperative examination. Treatment options include embolization and/or surgical resection. Therapeutic decisions should be adapted to the unique characteristics of the fistula on an individual basis. A new case of a primary arteriovenous fistula is described and discussed along with a complete review of the literature. The patient in this report presented with signs and symptoms of colonic ischemia without portal hypertension. The optimal treatment for this patient required a combination of embolization and surgical operation. The characteristics of these rare inferior mesenteric arteriovenous fistulas are examined and some considerations concerning diagnostic and therapeutic strategies that should be followed are presented. 相似文献
52.
Kudrat M. Abdulkadyrov Galina N. Salogub Nuriet K. Khuazheva Matthew L. Sherman Abderrahmane Laadem Rachel Barger Robert Knight Shankar Srinivasan Evangelos Terpos 《British journal of haematology》2014,165(6):814-823
This phase IIa study evaluated the safety and tolerability of sotatercept, and its effects on bone metabolism and haematopoiesis in newly diagnosed and relapsed multiple myeloma (MM) patients. Patients were randomized (4:1) to receive four 28‐d cycles of sotatercept (0·1, 0·3, or 0·5 mg/kg) or placebo. Patients also received six cycles of combination oral melphalan, prednisolone, and thalidomide (MPT). Thirty patients were enrolled; six received placebo and 24 received sotatercept. Overall, 25% of patients received all four sotatercept doses; 71% of sotatercept‐treated patients had ≥1 dose interruption mainly due to increases in haemoglobin levels. Grade ≥3 adverse events (AEs) were reported in 17% of patients receiving placebo and 58% receiving sotatercept. Grade 4 AEs in sotatercept‐treated patients were neutropenia, granulocytopenia, and atrial fibrillation (one patient each). In patients without bisphosphonate use, anabolic improvements in bone mineral density and in bone formation relative to placebo occurred, whereas bone resorption was minimally affected. Increases in haemoglobin levels, versus baseline, and the duration of the increases, were higher in the sotatercept‐treated patients, with a trend suggesting a dose‐related effect. Multiple doses of sotatercept plus MPT appear to be safe and generally well‐tolerated in MM patients. 相似文献
53.
Angelos Hatzakis Jeffrey V. Lazarus Evangelos Cholongitas Ricardo Baptista‐Leite Charles Boucher Cristian‐Silviu Busoi Sylvie Deuffic‐Burban Jagpreet Chhatwal Gamal Esmat Sharon Hutchinson Minerva‐Melpomeni Malliori Mojca Maticic Antons Mozalevskis Francesco Negro George A. Papandreou George V. Papatheodoridis Markus Peck‐Radosavljevic Homie Razavi Tatjana Reic Eberhard Schatz Nurdan Tozun Zobair Younossi Michael P. Manns 《Liver international》2020,40(2):260-270
The majority of people infected with chronic hepatitis C virus (HCV) in the European Union (EU) remain undiagnosed and untreated. During recent years, immigration to EU has further increased HCV prevalence. It has been estimated that, out of the 4.2 million adults affected by HCV infection in the 31 EU/ European Economic Area (EEA) countries, as many as 580 000 are migrants. Additionally, HCV is highly prevalent and under addressed in Eastern Europe. In 2013, the introduction of highly effective treatments for HCV with direct‐acting antivirals created an unprecedented opportunity to cure almost all patients, reduce HCV transmission and eliminate the disease. However, in many settings, HCV elimination poses a serious challenge for countries’ health spending. On 6 June 2018, the Hepatitis B and C Public Policy Association held the 2nd EU HCV Policy summit. It was emphasized that key stakeholders should work collaboratively since only a few countries in the EU are on track to achieve HCV elimination by 2030. In particular, more effort is needed for universal screening. The micro‐elimination approach in specific populations is less complex and less costly than country‐wide elimination programmes and is an important first step in many settings. Preliminary data suggest that implementation of the World Health Organization (WHO) Global Health Sector Strategy on Viral Hepatitis can be cost saving. However, innovative financing mechanisms are needed to raise funds upfront for scaling up screening, treatment and harm reduction interventions that can lead to HCV elimination by 2030, the stated goal of the WHO. 相似文献
54.
Yi Pu Lin Xiaoli Xiong Stephen A. Wharton Stephen R. Martin Peter J. Coombs Sebastien G. Vachieri Evangelos Christodoulou Philip A. Walker Junfeng Liu John J. Skehel Steven J. Gamblin Alan J. Hay Rodney S. Daniels John W. McCauley 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(52):21474-21479
The hemagglutinin (HA) of influenza A(H3N2) virus responsible for the 1968 influenza pandemic derived from an avian virus. On introduction into humans, its receptor binding properties had changed from a preference for avian receptors (α2,3-linked sialic acid) to a preference for human receptors (α2,6-linked sialic acid). By 2001, the avidity of human H3 viruses for avian receptors had declined, and since then the affinity for human receptors has also decreased significantly. These changes in receptor binding, which correlate with increased difficulties in virus propagation in vitro and in antigenic analysis, have been assessed by virus hemagglutination of erythrocytes from different species and quantified by measuring virus binding to receptor analogs using surface biolayer interferometry. Crystal structures of HA–receptor analog complexes formed with HAs from viruses isolated in 2004 and 2005 reveal significant differences in the conformation of the 220-loop of HA1, relative to the 1968 structure, resulting in altered interactions between the HA and the receptor analog that explain the changes in receptor affinity. Site-specific mutagenesis shows the HA1 Asp-225→Asn substitution to be the key determinant of the decreased receptor binding in viruses circulating since 2005. Our results indicate that the evolution of human influenza A(H3N2) viruses since 1968 has produced a virus with a low propensity to bind human receptor analogs, and this loss of avidity correlates with the marked reduction in A(H3N2) virus disease impact in the last 10 y.Surveillance of influenza viruses is essential for updating vaccines, for tracking the emergence of drug resistant viruses, and for monitoring zoonotic infections. It also gives important insights into the mechanisms of virus evolution. This is particularly the case for interpreting the correlation between antigenic differences and changes in the sialic acid receptor binding properties of the HA glycoprotein. The correlation in these two properties arises because of the close proximity on HA of binding sites for antibodies that neutralize virus infectivity and the sialic acid receptor binding pocket (1), and accounts for the observations that mutations that prevent antibody binding can also result in changes in receptor binding (2–7). Reduction in affinity of human H3N2 viruses for avian receptors since the beginning of the pandemic in 1968 has meant that by the 1990s viruses with reduced ability to agglutinate chicken erythrocytes had emerged (8, 9). Moreover, viruses isolated after 1999 were shown to have reduced affinity for both human and avian receptors, a feature that correlated with their poor growth properties in eggs and different cells in culture (9–14). The evolution of the HA has resulted in at least three key changes that influence receptor binding. Two sequential substitutions occurred at residue 225: in 2001–2002, a substitution Gly-225→Asp was accompanied by a Trp-222→Arg substitution, and in 2004–2005, an Asp-225→Asn substitution was accompanied by the substitution Ser-193→Phe (while maintaining arginine at position 222). Residue 226, a key amino acid in determining receptor specificity (15), also changed twice: before 2001, Leu-226→Val, and in 2004, Val-226→Ile (Fig. S1).To correlate these amino acid substitutions with the biological properties of the viruses, we have analyzed the receptor binding characteristics of H3N2 viruses isolated between 2001 and 2010, examined changes in their ability to infect cells in culture, and determined the structures of two HAs of virus isolates from 2004 and 2005 in the absence of receptor and complexed with a human receptor analog. The data show that the progressive decrease in binding of these viruses to human receptors from 2000 onward correlates with changes in the efficiencies of infection of cultured cells. Comparison of structural data for HAs of viruses from 1968, 2004, and 2005 explain how particular mutations that affect the conformation of the HA1 220-loop component of the receptor binding site define the receptor binding phenotype of recent H3N2 human influenza viruses. 相似文献
55.
Athyros VG Elisaf MS Alexandrides T Achimastos A Ganotakis E Bilianou E Karagiannis A Liberopoulos EN Tziomalos K Mikhailidis DP;Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes 《Angiology》2012,63(5):358-366
This post hoc analysis of the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) study assesses the 3? year incidence of new-onset diabetes (NOD) and related cardiovascular disease (CVD) events in patients with metabolic syndrome (MetS), after multifactorial (lifestyle and drug, including atorvastatin) intervention. Patients were randomized to group A (low-density lipoprotein cholesterol [LDL-C] target < 100 mg/dL) and group B (< 130 mg/dL). The incidence of NOD during the 42-month follow-up was very low, 0.83 to 1.00/100 patient-years in patients with MetS and MetS with impaired fasting glucose, respectively. Older age, increased waist circumference, and persistent MetS were determinants of NOD. One CVD nonfatal event occurred in the 28 patients with NOD. Our findings suggest that treating the characteristics of MetS is achievable and beneficial. New-onset diabetes incidence and CVD events were negligible and not different from what is expected in the general population. 相似文献
56.
The establishment of chest pain units (CPUs) in the USA and UK has led to improvements in the prognosis of patients with chest pain and myocardial infarction, optimizing access to specialized diagnostic and therapeutic facilities and reducing costs. To establish a uniform implementation of this type of service in Germany, the German Cardiac Society (DGK) founded a 'CPU task force' in 2007, which developed a set of standard requirements and a nationwide certification programme. The recommendations for minimum standard requirements were published in 2008. As of November 2011, 132 CPUs were certified and 36 units were in the certification process. The aim of the DGK is to certify as many as 250 centres (units) throughout Germany within the next 2 years, to provide nationwide coverage. Applications from Switzerland are also being filed. Public awareness campaigns in cooperation with national league soccer teams were organized to raise awareness of the importance for early diagnosis and treatment of cardiac diseases and to publicize the existence of these new facilities. The German model of CPU certification allows nationwide and prospectively European-wide standardization of patient care and to improve adherence to international guidelines. Coupled with awareness campaigns and with the launch of a German CPU Registry, this process is aimed at improving the education and treatment of patients with chest pain and to provide scientific information about the quality of patient care. 相似文献
57.
Thygesen K Mair J Giannitsis E Mueller C Lindahl B Blankenberg S Huber K Plebani M Biasucci LM Tubaro M Collinson P Venge P Hasin Y Galvani M Koenig W Hamm C Alpert JS Katus H Jaffe AS;the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care 《European heart journal》2012,33(18):2252-2257
58.
59.
60.